Shield Therapeutics plc (LON:STX – Get Free Report)’s share price was down 23.5% during trading on Thursday . The company traded as low as GBX 4.25 and last traded at GBX 4.40. Approximately 24,498,359 shares changed hands during trading, an increase of 1,091% from the average session volume of 2,056,888 shares. The stock had previously closed at GBX 5.75.
Shield Therapeutics Price Performance
The company has a debt-to-equity ratio of -199.87, a current ratio of 0.90 and a quick ratio of 2.16. The stock has a 50 day simple moving average of GBX 6.06 and a two-hundred day simple moving average of GBX 8. The company has a market cap of £42.25 million, a price-to-earnings ratio of -1.98 and a beta of 1.76.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
